Skip to Content

Gene Therapy for Rare Disorders Europe

Start Date:
Tuesday, 31 October, 2017
End Date:
Thursday, 2 November, 2017 4:30pm
Health & Nutrition

Gene Therapy for Rare Disorders Europe is devoted to overcoming these challenges, focusing specifically on the clinical, manufacturing, regulatory and reimbursement hurdles that need to be overcome for gene therapies to reach their full potential. Uniting leaders from Pfizer, GSK, Shire and uniQure, this meeting focusses specifically on delivering practical insights into developing the next generation of gene therapies that promise improved efficacy, enhanced safety and commercial viability.

Join your colleagues at this uniquely focused event and discover how to enhance every stage of your gene therapy development to achieve commercial success. Prices do not include VAT. Email for an Academic rate.PriceConference Earlybird (Book by 22/09/17): GBP 1799Conference + 1 Workshop Earlybird (Book by 22/09/17): GBP 2298Workshop only: GBP 599Conference (Standard rate): GBP 1999Conference + 1 Workshop (Standard rate): GBP 2498Speakers: Sven Kili (GSK), Wim Scheele (Pfizer), Detlev Parow (DAK), Sander van Deventer (uniQure), Christiane Niederlaender (UK Medicines and Healthcare Products Regulatory Agency (MHRA)), Aniz Girach (NightstarX), Hanspeter Rottensteiner (Shire), Jean-Philippe Combal (Vivet Therapeutics), Adrien Lemoine (Orchard Therapeutics)


De Vere Grand Connaught Rooms,
61 - 65 Great Queen Street,
United Kingdom

Organizer Details

Conference organized by Hanson Wade


Medical conference data provided by Meetings4Docs | Report a problem

Image Gallery